Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia treatment should use a modern, combined approach to effectively address hair loss.

Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.

Reflectance confocal microscopy confirms that yellow dots are signs of damaged hair follicles in alopecia areata.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

More exercise might link to hair loss, but other factors also matter.

The document concludes that changing the scalp's microbiome might be a new way to treat hair loss.

Low-dose oral minoxidil is safe and effective for treating hair loss, with most side effects being mild and reversible.

Cutaneous lupus can cause permanent hair loss by damaging hair follicles.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

Treatments for permanent hair loss from scarring aim to stop further loss, not regrow hair, and vary by condition, with partial success common.

The document concludes that early recognition and treatment of primary cicatricial alopecia is crucial to prevent permanent hair loss.

A genetic marker linked to a type of hair loss was found in most patients studied.

Accurate diagnosis and tailored treatments are crucial for managing hair loss in humans and animals.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Chinese patients with primary cicatricial alopecia often have folliculitis decalvans, benefit from treatment, but may experience relapse, with dermoscopy being a useful diagnostic tool.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Zinc supplements may be needed to treat hair loss in hypothyroidism.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

The document concludes that post-menopausal frontal fibrosing alopecia is a poorly understood condition that does not respond well to common treatments.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

Diagnosing hair loss disorders needs clinical, dermoscopic, and histological differences, and checking menstrual cycle, weight changes, drug therapy, and nail changes.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.

Alopecia areata, a type of hair loss, is likely an autoimmune disease with a genetic link, but its exact cause is still unknown.

No treatment has been proven to effectively stop hair loss or regrow hair in Frontal Fibrosing Alopecia, and more research is needed.

The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.

Patients with chronic graft-versus-host disease often have skin problems like vitiligo and alopecia areata.

Two patients with skin lupus were mistakenly thought to have a different scalp condition but improved with lupus treatment.

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.